

## Activation of human 5-HT<sub>3</sub> receptors via an allosteric transmembrane site

Stuart J. Lansdell, Chaitra Sathyaprakash, Anne Doward and Neil S. Millar

Department of Neuroscience, Physiology & Pharmacology, University College London,  
Gower Street, London, WC1E 6BT, United Kingdom

**Running title:** Allosteric activation of human 5-HT<sub>3</sub> receptors

**Corresponding author:**

Professor Neil S. Millar, Department of Neuroscience, Physiology & Pharmacology,  
University College London, Gower Street, London, WC1E 6BT, UK.

Tel.: +44-(0)20-7679-7241; Fax.: +44(0)20-7679-7243; Email: n.millar@ucl.ac.uk

Number of text pages: **33**

Number of tables: **1**

Number of figures: **10**

Number of references: **59**

Number of words in the Abstract: **250**

Number of words in the Introduction: **750**

Number of words in the Discussion: **1488**

**Abbreviations**

5-HT, 5-hydroxytryptamine; 5-HT<sub>3</sub>R, 5-hydroxytryptamine type 3 receptor; GABA<sub>A</sub>R,  $\gamma$ -aminobutyric acid type A receptor; nAChR, nicotinic acetylcholine receptor.

## Abstract

In common with other members of the Cys-loop family of pentameric ligand-gated ion channels, 5-hydroxytryptamine type 3 receptors (5-HT<sub>3</sub>Rs) are activated by the binding of a neurotransmitter to an extracellular orthosteric site, located at the interface of two adjacent receptor subunits. In addition, a variety of compounds have been identified that modulate agonist-evoked responses of 5-HT<sub>3</sub>Rs, and other Cys-loop receptors, by binding to distinct allosteric sites. In this study, we have examined the pharmacological effects of a group of monoterpene compounds on recombinant 5-HT<sub>3</sub>Rs expressed in *Xenopus* oocytes. Two phenolic monoterpenes (carvacrol and thymol) display allosteric agonist activity on human homomeric 5-HT<sub>3A</sub>Rs (64 ± 7% and 80 ± 4% of the maximum response evoked by the endogenous orthosteric agonist 5-HT, respectively). In addition, at lower concentrations, where agonist effects are less apparent, carvacrol and thymol act as potentiators of responses evoked by sub-maximal concentrations of 5-HT. In contrast, carvacrol and thymol have no agonist or potentiating activity on the closely related mouse 5-HT<sub>3A</sub>Rs. Using subunit chimeras containing regions of the human and mouse 5-HT<sub>3A</sub> subunits, and by use of site-directed mutagenesis, we have identified transmembrane amino acids that either abolish the agonist activity of carvacrol and thymol on human 5-HT<sub>3A</sub>Rs or are able to confer this property on mouse 5-HT<sub>3A</sub>Rs. In contrast, these mutations have no significant effect on orthosteric activation of 5-HT<sub>3A</sub>Rs by 5-HT. We conclude that 5-HT<sub>3A</sub>Rs can be activated by the binding of ligands to an allosteric transmembrane site, a conclusion that is supported by computer-docking studies.

## Introduction

5-hydroxytryptamine type 3 receptors (5-HT<sub>3</sub>Rs) are members of the Cys-loop family of ligand-gated ion channels (Lester et al., 2004; Nys et al., 2013), a neurotransmitter receptor family that also includes nicotinic acetylcholine receptors (nAChRs),  $\gamma$ -aminobutyric acid type A receptors (GABA<sub>A</sub>Rs), glycine receptors and invertebrate glutamate-gated chloride channels. Human 5-HT<sub>3</sub>Rs are thought to play a role in gastrointestinal function, nociception neurodevelopment and in a variety of psychiatric disorders (Lummis, 2012; Engel et al., 2013; Thompson, 2013). As a consequence, they are important targets for therapeutic drug discovery.

In common with other Cys-loop receptors, 5-HT<sub>3</sub>Rs are pentameric complexes and are activated by neurotransmitter (5-HT) binding to an extracellular site, located at the interface of adjacent subunits (Thompson et al., 2010; Nys et al., 2013). The agonist binding site of 5-HT<sub>3</sub>Rs and other Cys-loop receptors, which is also the binding site for competitive antagonists, is referred to as the orthosteric binding site and has been characterised extensively (Arias, 2000). In addition, a number of compounds have been identified that modulate agonist-evoked responses by binding to distinct allosteric sites on Cys-loop receptors (Hogg et al., 2005; Davies, 2011; Yevenes and Zeilhofer, 2011).

In addition to competitive antagonists, a variety of noncompetitive antagonists (negative allosteric modulators) of 5-HT<sub>3</sub>Rs have been identified that, typically, are thought to bind in the transmembrane region (Thompson, 2013). Examples of such compounds include verapamil (Hargreaves et al., 1996), cannabinoids (Barann et al., 2002), cannabidiol (Yang et al., 2010), hydrocortisone (Corradi et al., 2011), menthol (Ashoor et al., 2013) and PU02 (Trattinig et al., 2012). A variety of positive allosteric modulators of 5-HT<sub>3</sub>Rs have also been identified, including alcohols (Zhou and Lovinger, 1996), 5-hydroxyindole (van Hooft et al., 1997) colchicine (de Oliveira-Pierce et al., 2009) and 5-chloroindole (Newman et al., 2013).

Studies conducted with other Cys-loop receptors have also identified a variety of allosteric ligands displaying diverse pharmacological properties. For example, a large number of positive and negative allosteric modulators of nAChRs have been identified and there is evidence that at least some of these interact with an intrasubunit transmembrane site (Young et al., 2008; Collins et al., 2011). More recently, a group of nAChR allosteric agonists have been identified that cause receptor activation in the absence of an orthosteric agonist and have been proposed to act via an intrasubunit transmembrane site (Gill et al., 2011; Gill et al., 2012; Gill et al., 2013). Similarly, there is evidence for allosteric activation of other Cys-loop receptors including GABA<sub>A</sub>Rs (Amin and Weiss, 1993) and glutamate-gated chloride channels (Cully et al., 1994; Cully et al., 1996). Here we have examined the pharmacological properties of agonists acting on recombinant receptors containing the 5-HT<sub>3A</sub> subunit (homomeric 5-HT<sub>3A</sub>Rs) expressed in *Xenopus* oocytes.

As is discussed below, there is increasing evidence that monocyclic terpenes such as carvacrol, menthol, propofol and thymol act as allosteric modulators of several Cys-loop receptors. Typically, such compounds lack direct agonist activity but can modulate agonist-evoked responses, acting as either positive or negative allosteric modulators. In the present study we provide evidence that human 5-HT<sub>3A</sub>Rs can be activated by monocyclic terpenes (carvacrol and thymol) via an allosteric transmembrane site. Carvacrol and thymol are structural isomers (see Figure 1) and are components of naturally-occurring essential oils from plants such as thyme and oregano. They have been reported to have antibacterial, anti-inflammatory, anti-oxidant and vasorelaxant effects (Baser, 2008; Peixoto-Neves et al., 2009). In addition, both carvacrol and thymol are used as acaricides to control mite (*Varroa destructor*) infestation of honeybee hives (Damiani et al., 2009). There is evidence that carvacrol and thymol are positive allosteric modulators of both invertebrate and mammalian GABA<sub>A</sub>Rs (Priestley et al., 2003; García et al., 2006; Reiner et al., 2013). In addition, carvacrol has also been reported to inhibit the binding of nicotine to nAChRs via a site that is

distinct from the conventional orthosteric binding site (Tong et al., 2012). Carvacrol and thymol have close chemical similarity to propofol, an intravenous anaesthetic, that acts as both a positive allosteric modulator and direct activator of GABA<sub>A</sub>Rs (Hales and Lambert, 1991) and has been shown to interact with a transmembrane binding site in both GABA<sub>A</sub>Rs (Chiara et al., 2013; Yip et al., 2013) and nAChRs (Jayakar et al., 2013). In addition, propofol has been shown to inhibit 5-HT<sub>3</sub>Rs (Barann et al., 2000).

In summary, we provide evidence that carvacrol and thymol are species-selective 5-HT<sub>3</sub>Rs agonists, activating human but not mouse receptors. By means of subunit chimeras and site-directed mutagenesis we have obtained evidence indicating that carvacrol and thymol interact with a transmembrane site and act as allosteric agonists on human 5-HT<sub>3</sub>Rs.

## Materials and Methods

### Materials

Carvacrol (5-isopropyl-2-methylphenol), chlorothymol (4-chloro-2-isopropyl-5-methylphenol), linalool (3,7-dimethylocta-1,6-dien-3-ol), menthol (2-isopropyl-5-methylcyclohexanol), *p*-cymene (1-methyl-4(1-methylethyl)benzene), propofol (2,6-diisopropylphenol), thymol (2-isopropyl-5-methylphenol) and *p*-thymol (4-isopropyl-3-methylphenol) were obtained from Sigma-Aldrich. Citral (3,7-dimethylocta-2,6-dienal) was obtained from Merck,  $\alpha$ -terpineol (2-(4-methyl-1-cyclohex-3-enyl)propan-2-ol) was obtained from Acros-Organics/Thermo Fisher Scientific and tropisetron from LKT Laboratories.

### Plasmids

Human 5-HT3A and 5-HT3B subunits in plasmid pcDM8 (Davies et al., 1999) were a gift from Ewen Kirkness, Institute for Genomic Research, Maryland. Mouse 5-HT3A subunit cDNA (Maricq et al., 1991) was a gift from David Julius, UCSF and was subcloned into plasmid pRK5, as described previously (Harkness and Millar, 2001). A construct containing the human  $\alpha 7$  nAChR subunit in plasmid pSP64GL has been described previously (Broadbent et al., 2006). Subunit chimeras containing the extracellular domain of either the rat or human nAChR  $\alpha 7$  subunit, fused to the transmembrane and C-terminal domains of the mouse 5-HT3A subunit, have also been described previously (Cooper and Millar, 1998; Craig et al., 2004).

### Construction of 5-HT3A subunit chimeras

Human/mouse (h/m) and mouse/human (m/h) 5-HT3A subunit chimeras were constructed which contained the extracellular N-terminal domain of the 5-HT3A subunit from one species fused to the transmembrane and intracellular domains of the 5-HT3A subunit from the other species (referred to as h/m 5-HT3A and m/h 5-HT3A subunit chimeras, respectively). The m/h 5-HT3A subunit chimera in expression vector pRK5 was constructed by using an

existing *Bcl*I site in the mouse 5-HT3A subunit cDNA (immediately upstream of the first transmembrane domain) and a *Bam*HI site that was introduced into the human 5-HT3A subunit cDNA by site directed mutagenesis. The h/m 5-HT3A subunit chimera in expression vector pcDNA3.1 was constructed from an existing rat  $\alpha 7^{(V201)}$ /mouse 5-HT3A subunit chimera (Cooper and Millar, 1998) and the human 5-HT3A subunit cDNA containing a *Bam*HI site, introduced as described above. Construction of the h/m 5-HT3A chimera resulted in a codon for valine being changed to a codon for glycine at the junction of the human and mouse 5-HT3A cDNAs. Site-directed mutagenesis was performed on the h/m 5-HT3A subunit chimera to recreate the valine codon.

### Site directed mutagenesis and cRNA synthesis

Site-directed mutagenesis was performed on human and mouse 5-HT3A subunit cDNAs using the QuikChange mutagenesis kit (Stratagene) and verified by nucleotide sequencing. The numbering of amino acids changed by site-directed mutagenesis is based on that described previously for the human 5-HT3A subunit (NCBI accession number BAA08387) and for the mouse 5-HT3A subunit (NCBI accession number NP\_038589).

### *Xenopus* Oocyte Electrophysiology

*Xenopus laevis* oocytes were isolated and defolliculated, as described previously (Young et al., 2007). Expression of recombinant 5-HT<sub>3</sub>Rs was achieved by injection of either cRNA (6 – 12 ng) into the cytoplasm or by injection of plasmid cDNA constructs (10 – 30 ng) into the oocyte nuclei. *In vitro* synthesis of cRNA was performed using the mMessage mMachine SP6 or T7 kits (Ambion). Oocytes were injected with a volume of 32.2nl using a Drummond variable volume micro-injector. Two electrode voltage-clamp recordings were performed as described previously (Young et al., 2007). Agonists and allosteric modulators were applied to voltage-clamped oocytes using a computer-controlled gravity perfusion system (ALA Scientific Instruments). Typically agonists were applied for 3-20s and allosteric modulation of



agonist-evoked responses determined by pre-application of modulators for 2 minutes, followed by their co-application with agonists.

### **Cell culture and transfection**

The mammalian cell line tsA201, derived from the human embryonic kidney 293 cell line, was obtained from Dr. William Green (University of Chicago, Chicago, IL). Cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Paisley, UK) containing 2 mM L-GlutaMAX (Invitrogen) plus 10% heat-inactivated fetal calf serum (Sigma, Poole, UK) with penicillin (100 U/ml) and streptomycin (100 µg/ml) and were maintained in a humidified incubator containing 5% CO<sub>2</sub> at 37°C. Cells were transiently transfected with a plasmid expression vector encoding the human 5-HT<sub>3A</sub> subunit cDNA (pcDNA3) using Effectene transfection reagent (QIAGEN, Crawley, UK) according to the manufacturer's instructions. Cells were transfected overnight and assayed for expression approximately 40 to 48 h after transfection.

### **Radioligand binding**

Radioligand binding studies were performed with [<sup>3</sup>H]-GR65630 (70.1 Ci/mmol; Perkin Elmer, Seer Green, UK), essentially as described previously (Baker et al., 2004). Membrane preparations were isolated from transfected tsA201 in 10mM phosphate buffer (pH 7.2) containing the protease inhibitors leupeptin and aprotinin (2 µg/ml) and pepstatin (1 µg/ml). Binding experiments were performed in buffer containing 0.5% BSA to reduce non-specific binding. Samples were incubated with radioligand (10 nM [<sup>3</sup>H]-GR65630) in a total volume of 300 µl for 2 hours at 4°C. Competition studies were carried out using [<sup>3</sup>H]-GR65630 (10 nM) and varying concentrations (0.01 nM to 1 mM) of competing ligands (5-HT, carvacrol or thymol). Samples were assayed by filtration onto Whatman GF/B filters pre-soaked in 0.5% polyethyleneimine, followed by rapid washing with ice-cold 10 mM phosphate buffer using a Brandel cell harvester and levels of bound radioligand determined by scintillation counting as described previously (Baker et al., 2004).

## Statistical analysis

Unpaired Student's t-tests were used throughout (unless otherwise stated). Equal variance between control and experimental groups was assumed.

## Computer docking simulations

Computer docking simulations with carvacrol and thymol were performed using AUTODOCK 4 (Morris et al., 1998) with a homology model of the transmembrane domain of two adjacent subunits of the human 5-HT<sub>3A</sub>R (see Data Supplement), based on the 3.5Å resolution X-ray structure of the mouse 5-HT<sub>3A</sub>R (Hassaine et al., 2014). A grid was defined which encompassed the entire transmembrane domain of two adjacent subunits in the 5-HT<sub>3A</sub>R homology model, together with the corresponding intersubunit transmembrane region. A 'blind docking' approach was employed (Hetényi and van der Spoel, 2006) in which no assumptions were made concerning where within this transmembrane region ligands might bind. Predicted Gibbs free energy of binding ( $\Delta G$ ) was calculated as described (Morris et al., 1998; Huey et al., 2007).

## Results

### Activation of 5-HT<sub>3A</sub>Rs by carvacrol and thymol

Two-electrode voltage-clamp recording was used to examine the pharmacological properties of a series of monocyclic terpenes (Figure 1) on 5-HT<sub>3</sub>Rs expressed in *Xenopus* oocytes. Two phenolic monoterpenes (carvacrol and thymol) resulted in activation of homomeric 5-HT<sub>3</sub>Rs containing the human 5-HT<sub>3A</sub> subunit (Figure 2). In contrast, no agonist activation was observed on human 5-HT<sub>3A</sub>Rs with *p*-thymol (a structural isomer of carvacrol and thymol) (Figure 2) or with any of the other monoterpenes examined (see Figure 1 for details of all compounds tested). With mouse 5-HT<sub>3A</sub>Rs, none of the compounds tested (Figure 1), including carvacrol and thymol, had any agonist activity, indicating that the agonist effect of carvacrol and thymol on 5-HT<sub>3A</sub>Rs is species-selective. In contrast to the rapid activation of human 5-HT<sub>3A</sub>Rs by the endogenous agonist 5-HT, activation by carvacrol and thymol occurred with a significantly slower onset (Figure 2). Whereas responses to 5-HT reached a plateau within  $0.6 \pm 0.04$  s ( $n=18$ ), activation by carvacrol or thymol was significantly slower ( $p < 0.001$  for both compounds), reaching a plateau within  $62 \pm 7$  s ( $n=7$ ) and  $48 \pm 3$  s ( $n=7$ ), respectively (Figure 2). Agonist responses evoked by 5-HT, carvacrol and thymol were blocked completely by the orthosteric antagonist tropisetron. Long applications of 5-HT (>7 minutes) resulted in complete desensitisation of human 5-HT<sub>3A</sub>Rs (Fig. 3). Similarly, both carvacrol and thymol caused receptor desensitisation over a similar timescale (Fig. 3). After complete desensitisation of human 5-HT<sub>3A</sub>Rs with 5-HT, a subsequent co-application of either carvacrol or thymol failed to reactivate desensitised receptors (not shown).

### Potentiation of 5-HT<sub>3A</sub>Rs by carvacrol and thymol

At lower concentrations (<10  $\mu$ M), carvacrol and thymol did not display clear agonist activity on human 5-HT<sub>3A</sub>Rs but both compounds potentiated responses to submaximal concentrations of 5-HT (Figure 4A and 4B), resulting in a leftward shift in the dose-response curve for 5-HT (Figure 4C and 4D). With an approximate  $EC_{25}$  concentration of 5-HT (0.6

$\mu\text{M}$ ), co-application of either carvacrol (10  $\mu\text{M}$ ) or thymol (10  $\mu\text{M}$ ) to human 5-HT<sub>3A</sub>Rs significantly potentiated responses evoked by 5-HT (2.6  $\pm$  0.2 fold change in EC<sub>50</sub> for 5-HT with both compounds;  $p < 0.001$ ,  $n = 9$ ). However, when carvacrol or thymol (at either a sub-maximal or maximal concentration) were co-applied with a saturating concentration of 5-HT to human 5-HT<sub>3A</sub>Rs, no potentiation of the maximal current response was observed (Figure 4). As was observed for the agonist-activation, potentiation by carvacrol and thymol of responses evoked by sub-maximal concentrations of 5-HT was species-selective. No evidence of potentiation of 5-HT evoked responses was observed on the mouse 5-HT<sub>3A</sub>R with a range of concentrations of carvacrol or thymol (1-300  $\mu\text{M}$ ). Therefore, both the agonist and potentiating effects of carvacrol and thymol on 5-HT<sub>3A</sub>Rs are species-selective. In addition, none of the other compounds examined in this study (Figure 1) had any activity in potentiating responses to 5-HT on either human or mouse 5-HT<sub>3A</sub>Rs.

### Human/mouse 5-HT<sub>3A</sub> subunit chimeras

With the aim of investigating the mechanism of receptor modulation by carvacrol and thymol, artificial 5-HT<sub>3A</sub> subunit chimeras were constructed. Human/mouse (h/m) and mouse/human (m/h) chimeras were generated that contained the N-terminal extracellular domain of one subunit fused to the transmembrane and C-terminal domain of the other subunit (h/m 5-HT<sub>3A</sub> and m/h 5-HT<sub>3A</sub> subunit chimeras). Carvacrol and thymol (but not their structural isomer, *p*-thymol) displayed agonist activity on the m/h 5-HT<sub>3A</sub> subunit chimera (Figure 2C) but had no agonist effect on the h/m 5-HT<sub>3A</sub> subunit chimera (Figure 2D). This would imply that the agonist activity of carvacrol and thymol is mediated via the C-terminal (transmembrane) domain of the 5-HT<sub>3A</sub> subunit. Carvacrol displayed slightly higher potency ( $P < 0.001$ ) on human 5-HT<sub>3A</sub> than on the m/h 5-HT<sub>3A</sub> chimera (Fig. 5 and Table 1) whereas there was no significant difference between in the potency of thymol on these receptors. As had been observed with human 5-HT<sub>3A</sub>Rs, activation of receptors containing the m/h 5-HT<sub>3A</sub> subunit chimera was significantly slower with carvacrol and thymol than when activated by 5-HT (Figure 2C and 2D). Agonist dose-response curves (with 5-HT,

carvacrol and thymol) were constructed for 5-HT<sub>3</sub>Rs containing wild-type and chimeric subunits (Figure 5) and  $EC_{50}$  values are summarized in Table 1.

### **Mutagenesis of the human 5-HT3A subunit**

Examination of the amino acid sequences of the human and mouse 5-HT3A subunits revealed a high degree of conservation throughout the subunit, with only five amino acid differences in the four transmembrane regions (TM1-4; Figure 6). Given the evidence that monocyclic terpenes bind within the transmembrane domain of other Cys-loop receptors (see Discussion for more details), together with our studies of 5-HT3A subunit chimeras, we examined the effect of mutating non-conserved amino acids within the transmembrane regions of human and mouse 5-HT3A subunits. The five non-conserved amino acids in the transmembrane regions of human 5-HT3A were mutated individually to their corresponding amino acid in the mouse subunit and their effect on agonist activation examined (Table 1). The most dramatic effect was seen with the mutation of a single methionine to a valine (M259V) in the first transmembrane domain (TM1), which resulted in the almost complete abolition of agonist activation by carvacrol and thymol (Figure 7 and Table 1). In contrast, the M259V mutation had no significant effect on activation by the orthosteric agonist 5-HT (Figure 7 and Table 1).

### **Mutagenesis of the mouse 5-HT3A subunit**

Mutations were also constructed in the mouse 5-HT3A subunit with the aim of examining whether a minimal set of amino acid changes could be identified that conferred on mouse 5-HT<sub>3A</sub>Rs the ability to be activated by carvacrol and thymol. A single mutation (V264M), analogous to the M259V mutation in human 5-HT3A subunit, had no significant effect on the pharmacological effects of carvacrol or thymol (Table 1). However, progressively larger agonist responses were observed with carvacrol and thymol in mouse 5-HT<sub>3A</sub>Rs containing two, three or four amino acid mutations located within the TM1 domain (Table 1). For example, a mouse 5-HT3A subunit containing just four transmembrane mutations in TM1

(A251V, V264M, C270Y and D274N) generated a homomeric 5-HT<sub>3A</sub>R in which agonist responses to carvacrol and thymol were  $32 \pm 3\%$  and  $32 \pm 1\%$ , respectively, of the maximal response to 5-HT (Figure 8).

### **Heteromeric 5-HT<sub>3A/3B</sub>Rs**

Although 5-HT<sub>3A</sub> subunits form homomeric 5-HT<sub>3A</sub>Rs efficiently in *Xenopus* oocytes, they are also able to co-assemble with 5-HT<sub>3B</sub> subunits to generate heteromeric 5-HT<sub>3A/3B</sub>Rs (Davies et al., 1999). Consequently, the effect of carvacrol and thymol was examined on human heteromeric 5-HT<sub>3A/3B</sub>Rs, by co-expression of human 5-HT<sub>3A</sub> and 5-HT<sub>3B</sub> subunits in *Xenopus* oocytes. As had been found with human homomeric 5-HT<sub>3A</sub>Rs, both carvacrol and thymol acted as agonists on heteromeric 5-HT<sub>3A/3B</sub>Rs. However, in comparison to responses evoked by the endogenous agonist 5-HT, carvacrol and thymol both generated significantly smaller maximal agonist responses on the heteromeric receptor ( $P < 0.05$  and  $P < 0.001$ , respectively; Table 1).

### **Radioligand binding**

Competition radioligand binding studies were performed to examine the ability of agonists (5-HT, carvacrol and thymol) to displace the binding of [<sup>3</sup>H]-GR65630, a 5HT<sub>3</sub>R-selective ligand, from its extracellular binding site (Figure 9). In agreement with previous binding studies (Barann et al., 2002), the orthosteric agonist 5-HT caused complete displacement of [<sup>3</sup>H]-GR65630 in a concentration-dependent manner, with an  $IC_{50}$  of  $1.70 \pm 0.14 \mu\text{M}$  ( $n=3$ ). In contrast, neither carvacrol nor thymol displaced [<sup>3</sup>H]-GR65630 binding, even at the highest concentrations tested (Figure 9).

### **Computer docking**

A plausible explanation for the activation of human 5-HT<sub>3</sub>Rs by carvacrol and thymol is that this occurs via a transmembrane binding site, rather than via the conventional orthosteric binding site. Computer docking studies were performed to examine the interaction of

carvacrol and thymol with a 5-HT<sub>3A</sub>R homology model. In both cases, the lowest energy docked conformations of the two ligands (-6.1 kcal/mol for carvacrol and -5.8 kcal/mol for thymol) were in very close proximity (within 6Å) to the side chain of M259, the amino acid in TM1 of the human 5-HT<sub>3A</sub> subunit which, when mutated to valine, largely abolished agonist activation by carvacrol and thymol. The position of the lowest energy docked conformation of the two ligands was almost identical and was located in the intersubunit cavity between TM1 and TM2 helices of one subunit and the TM3 and TM4 helices of the adjacent subunit (Figure 10).

## Discussion

It is well established that conventional agonists activate Cys-loop receptors, such as the 5-HT<sub>3</sub>R, by binding to an extracellular site located at the interface of two adjacent subunits (Thompson et al., 2010). This binding site for agonists and competitive antagonists is commonly referred to as the orthosteric site. However, there is increasing evidence indicating that Cys-loop receptors can be activated by allosteric ligands, interacting at sites that are distinct from the orthosteric site. For example, nAChRs can be activated by ligands binding to a transmembrane allosteric site in the absence of orthosteric agonists such as acetylcholine (Gill et al., 2011; Gill et al., 2012). In addition, ivermectin, a macrocyclic lactone, activates glutamate-gated chloride channels in the absence of the endogenous agonist glutamate (Cully et al., 1994; Cully et al., 1996) via a transmembrane binding site (Hibbs and Gouaux, 2011). Similarly, pentobarbital, a barbiturate anaesthetic, causes allosteric activation of GABA<sub>A</sub>Rs (Amin and Weiss, 1993). Also, in addition to being an allosteric modulator of GABA<sub>A</sub>Rs, propofol causes direct receptor activation at higher concentrations (Hales and Lambert, 1991). Activation by both orthosteric and allosteric agonists has also been reported for G protein-coupled receptors (Langmead and Christopoulos, 2006).

Previous studies with 5-HT<sub>3</sub> receptors have demonstrated allosteric modulation (both potentiation or inhibition) of responses evoked by orthosteric agonists such as 5-HT (Thompson, 2013). For example, positive allosteric modulation of 5-HT<sub>3</sub>Rs has been observed with alcohols (Machu and Harris, 1994), volatile anaesthetics (Machu and Harris, 1994), colchicine (de Oliveira-Pierce et al., 2009) and 5-chloroindole (Newman et al., 2013). In addition, menthol (a monoterpene) has been shown to act as an allosteric inhibitor of human 5-HT<sub>3</sub>Rs (Ashoor et al., 2013). Inhibitory effects have also been observed on human 5-HT<sub>3</sub>Rs with propofol, an intravenous anaesthetic with close chemical similarity to thymol and carvacrol (Barann et al., 2008).



Thymol has been reported previously to act as a positive allosteric modulator of GABA<sub>A</sub>Rs (Priestley et al., 2003; García et al., 2006). Similarly, carvacrol and chlorothymol have been reported to influence radioligand binding to GABA<sub>A</sub>Rs in a manner that is consistent with them acting as positive allosteric modulators (Reiner et al., 2013). Carvacrol has also been reported to inhibit the binding of nicotine to nAChRs via a site that is distinct from the orthosteric binding site (Tong et al., 2012). Therefore, these previous studies with Cys-loop receptors are consistent with our data from 5-HT<sub>3</sub>Rs, indicating that modulation by thymol and carvacrol occurs via an allosteric site.

Given the chemical similarity of carvacrol and thymol, it seems probable that the two compounds we have identified with allosteric agonist activity on human 5-HT<sub>3</sub>Rs and also related phenol monoterpenes, such as propofol, might interact at a broadly similar binding site on Cys-loop receptors. A binding site for propofol has been identified by photolabeling in the transmembrane domain of GABA<sub>A</sub>Rs (Chiara et al., 2013; Yip et al., 2013) and of nAChRs (Jayakar et al., 2013). Similarly, a transmembrane binding site for propofol has been identified in the bacterial pentameric ion channel GLIC by means of X-ray crystallography (Nury et al., 2011). Electrophysiological studies with a variety of pentameric ligand-gated ion channels provides additional evidence that propofol interacts via a transmembrane site (Ghosh et al., 2013; Lynagh and Laube, 2014). This evidence, indicating that propofol interacts with a transmembrane binding site of pentameric receptors, is consistent with our experimental data indicating that carvacrol and thymol may interact with a transmembrane site in 5-HT<sub>3</sub>Rs. We have shown, for example, that carvacrol and thymol act as agonists of receptors containing mouse/human 5-HT<sub>3A</sub> subunit chimeras but not with human/mouse subunit chimeras. Carvacrol and thymol activate human 5-HT<sub>3</sub>Rs with a significantly slower onset than the endogenous orthosteric agonist 5-HT ( $p < 0.001$ ). A similar difference in the onset of receptor activation has been observed with nAChRs activated by either the orthosteric agonist acetylcholine or by allosteric agonists acting via transmembrane binding site (Gill et al., 2011; Gill et al., 2012).

Our studies with subunit chimeras, suggest that the transmembrane region may be important in mediating the agonist action of carvacrol and thymol on human 5-HT<sub>3A</sub>Rs. In addition, we have found that a single point mutation in TM1 (M259V), which has no significant effect on agonist activation by 5-HT, results in the almost complete block of the agonist activity of carvacrol and thymol. It is not uncommon to find that a single mutation can abolish a pharmacological effect but for a single mutation (or even a small number of mutations) to be insufficient to confer a pharmacological property. Nevertheless, we have found that a few as two mutations in TM1 can confer on mouse 5-HT<sub>3A</sub>Rs the ability to be activated by carvacrol and thymol and that increasingly robust agonist activation is seen receptors containing three or four mutations in TM1.

In agreement with previous studies (Barann et al., 2002), competition radioligand binding experiments with the orthosteric ligand [<sup>3</sup>H]-GR65630 demonstrated that the endogenous agonist 5-HT caused complete displacement of the radioligand in a concentration-dependent manner. In contrast, no significant displacement of [<sup>3</sup>H]-GR65630 binding was observed with either carvacrol or thymol. This provides evidence that carvacrol and thymol do not bind the conventional orthosteric agonist binding site and is consistent with them acting at a distinct allosteric site.

Computer-docking studies predicted that the lowest energy docked conformation of carvacrol and thymol was in very close proximity to M259, the amino acid which, when mutated, had a profound effect on agonist activation by carvacrol and thymol on human 5-HT<sub>3A</sub>Rs (but had no significant effect on activation by 5-HT). We are conscious that computer-docking studies using receptor homology models should be interpreted with a degree of caution. Nevertheless, the results of these docking studies are consistent with the hypothesis that carvacrol and thymol are interacting at a transmembrane site.

We found that human heteromeric 5-HT<sub>3A/3B</sub>Rs were activated significantly less strongly by carvacrol and thymol than human homomeric 5-HT<sub>3A</sub>Rs. Comparison of the amino acid sequence of the human 5-HT<sub>3B</sub> subunit, with that of the 5-HT<sub>3A</sub> subunit, revealed that at the position analogous to the M259V mutation in the human 5-HT<sub>3A</sub> subunit, the human 5-HT<sub>3B</sub> subunit contained a valine. In this respect the human 5-HT<sub>3B</sub> subunit resembles more closely the mouse, rather than the human, 5-HT<sub>3A</sub> subunit and may provide an explanation for the lower efficacy of carvacrol and thymol on human homomeric 5-HT<sub>3A</sub>Rs.

An interesting aspect of the present study is that carvacrol and thymol were found to have species-selective effect on 5-HT<sub>3</sub>Rs (acting as agonists on human 5-HT<sub>3</sub>Rs but not on mouse 5-HT<sub>3</sub>Rs). In this respect, these findings are similar to a previous study that examined the effects of colchicine on 5-HT<sub>3</sub>Rs. Colchicine acts as a positive allosteric modulator of human 5-HT<sub>3</sub>Rs but as an inhibitor of mouse 5-HT<sub>3</sub>Rs (de Oliveira-Pierce et al., 2009). However, whereas we have obtained evidence that is consistent with thymol and carvacrol interacting with a transmembrane site, colchicine has been proposed to act via an extracellular allosteric binding site (de Oliveira-Pierce et al., 2009).

Previous studies with  $\alpha 7$  nAChRs have identified positive allosteric modulators (PAMs) that can be classified as being either 'type I' or type 'type II' PAMs, depending on their effects on receptor desensitisation (Bertrand and Gopalakrishnan, 2007). Type I PAMs have little or no effect on receptor desensitisation, whereas type II PAMs cause a marked reduction in the otherwise very rapid rate of agonist-evoked desensitisation of  $\alpha 7$  nAChRs. In addition, type II PAMs (but not type I) and also non-desensitising  $\alpha 7$ -selective allosteric agonists facilitate reactivation of desensitised  $\alpha 7$  nAChRs (Young et al., 2008; Collins et al., 2011; Gill et al., 2011). The failure of carvacrol and thymol to reactivate desensitised 5-HT<sub>3</sub>Rs indicates that they have properties that are more similar those of type I PAMs of  $\alpha 7$  nAChRs.

Our primary focus in this study has been to investigate the phenomenon of agonist activation of human 5-HT<sub>3A</sub>Rs by carvacrol and thymol. Our main conclusion is that these compounds are acting as allosteric agonists at a site that is distinct from the extracellular orthosteric agonist-binding site for the endogenous agonist 5-HT. In addition, our data are consistent with the binding site for carvacrol and thymol being in the transmembrane domain. Although not the primary focus of the present study, it is possible that the allosteric binding site for carvacrol and thymol could be exploited as a potential target for the development of novel receptor-selective ligands and therapeutic drugs.

In summary, a combination of factors suggest that the most plausible explanation for the agonist activation of human 5-HT<sub>3</sub>Rs by carvacrol and thymol is that this occurs via an interaction with the transmembrane domain, rather than at the conventional orthosteric binding site. The onset of activation by these compounds is significantly slower than with activation by the orthosteric agonist 5-HT, a finding that has been reported with orthosteric and allosteric (transmembrane) agonists of nAChRs (Gill et al., 2011; Gill et al., 2012). It is also consistent with studies obtained with chimeric and mutated 5-HT<sub>3</sub>R subunits. Computer docking simulations with a 5-HT<sub>3A</sub>Rs homology model are also consistent with this interpretation and suggest that allosteric activation by carvacrol and thymol may occur via an intersubunit binding site. Interestingly, an intersubunit binding site has been proposed as the site of action of several negative allosteric modulators of 5-HT<sub>3</sub>Rs including hydrocortisone (Corradi et al., 2011) and PU02 (Trattinig et al., 2012), albeit at a site located somewhat higher in the transmembrane domain.

## Authorship Contributions

*Participated in research design:* Lansdell and Millar.

*Conducted experiments:* Lansdell, Sathyaprakash and Doward.

*Performed data analysis:* Lansdell, Sathyaprakash and Millar.

*Wrote or contributed to writing the manuscript:* Lansdell and Millar.

## References

- Amin J and Weiss DS (1993) GABA<sub>A</sub> receptor needs two homologous domains of the  $\beta$ -subunit for activation by GABA but not by pentobarbital. *Nature* **366**:565-569.
- Arias HR (2000) Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors. *Neurochem Int* **36**:595-645.
- Ashoor A, Nordman JC, Veltri D, Yang K-HS, Shuba Y, Kury LA, Sadek B, Howarth FC, Shehu A, Kabbani N and Oz M (2013) Menthol inhibits 5-HT<sub>3</sub> receptor-mediated currents. *J Pharm Exp Ther* **247**:398-409.
- Baker ER, Zwart R, Sher E and Millar NS (2004) Pharmacological properties of  $\alpha 9\alpha 10$  nicotinic acetylcholine receptors revealed by heterologous expression of subunit chimeras. *Mol Pharmacol* **65**:453-460.
- Barann M, Dilger JP, Bönisch H, Göthert M, Dybek A and Urban BW (2000) Inhibition of 5-HT<sub>3</sub> receptors by propofol: equilibrium and kinetic measurements. *Neuropharmacol* **39**:1064-1074.
- Barann M, Linden I, Witten S and Urban BW (2008) Molecular actions of propofol on human 5-HT<sub>3A</sub> receptors: enhancement as well as inhibition by closely related phenol derivatives. *Anesth Analg* **106**:846-857.
- Barann M, Molderings G, Brüss M, Bönisch H, Urban BW and Göthert M (2002) Direct inhibition by cannabinoids of human 5-HT<sub>3A</sub> receptors: probable involvement of an allosteric modulatory site. *Br J Pharmacol* **137**:589-596.
- Baser KHC (2008) Biological and pharmacological activities of carvacrol and carvacrol bearing essential oils. *Curr Pharm Des* **14**:3106-3119.
- Bertrand D and Gopalakrishnan M (2007) Allosteric modulation of nicotinic acetylcholine receptors. *Biochem Pharmacol* **74**:1155-1163.
- Broadbent S, Groot-Kormelink PJ, Krashia PA, Harkness PC, Millar NS, Beato M and Sivilotti LG (2006) Incorporation of the  $\beta 3$  subunit has a dominant-negative effect on the

- function of recombinant central-type neuronal nicotinic receptors. *Mol Pharmacol* **70**:1350-1356.
- Chiara DC, Jayakar SS, Zhou X, Zhang X, Savechenkov PY, Bruzik KS, Miller KW and Cohen JB (2013) Specificity of intersubunit general anesthetic-binding sites in the transmembrane domain of the human  $\alpha 1\beta 3\gamma 2$   $\gamma$ -aminobutyric acid type A (GABA<sub>A</sub>) receptor. *J Biol Chem* **288**:19243-19357.
- Collins T, Young GT and Millar NS (2011) Competitive binding at a nicotinic receptor transmembrane site of two  $\alpha 7$ -selective positive allosteric modulators with differing effects on agonist-evoked desensitization. *Neuropharmacol* **61**:1306-1313.
- Cooper ST and Millar NS (1998) Host cell-specific folding of the neuronal nicotinic receptor  $\alpha 8$  subunit. *J Neurochem* **70**:2585-2593.
- Corradi J, Andersen N and Bouzat C (2011) A novel mechanism of modulation of the 5-HT<sub>3A</sub> receptors by hydrocortisone. *Biophys J* **100**:42-51.
- Craig PJ, Bose S, Zwart R, Beattie RE, Folly EA, Johnson LR, Bell E, Evens NM, Benedetti G, Pearson KH, McPhie GI, Volsen SG, Millar NS, Sher E and Broad LM (2004) Stable expression and characterisation of a human  $\alpha 7$  nicotinic subunit chimera: a tool for functional high-throughput screening. *Eur J Pharmacol* **502**:31-40.
- Cully DF, Pareiss PS, Liu KK, Schaeffer JM and Arena JP (1996) Identification of a *Drosophila melanogaster* glutamate-gated chloride channel sensitive to the antiparasitic agent avermectin. *J Biol Chem* **271**:20187-20191.
- Cully DF, Vassilatis DK, Liu KK, Pareiss PS, Van der Ploeg LHT, Schaeffer JM and Arena JP (1994) Cloning of an avermectin-sensitive glutamate-gated chloride channel from *Caenorhabditis elegans*. *Nature* **371**:707-711.
- Damiani N, Gende LB, Bailac P, Marcangeli JA and Eguaras MJ (2009) Acaricidal and insecticidal activity of essential oils on *Varroa destructor* (Acari: Varroidae) and *Apis mellifera* (Hymenoptera: Apidae). *Parasitol Res* **106**:145-152.
- Davies PA (2011) Allosteric modulation of the 5-HT<sub>3</sub> receptor. *Curr Opin Pharmacol* **11**:75-80.

- Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales TG and Kirkness EF (1999)  
The 5-HT<sub>3B</sub> subunit is a major determinant of serotonin-receptor function. *Nature*  
**397**:359-363.
- de Oliveira-Pierce AN, Zhang R and Machu TK (2009) Colchicine: a novel positive allosteric  
modulator of the human 5-hydroxytryptamine<sub>3A</sub> receptor. *J Pharm Exp Ther* **329**:838-  
847.
- Engel M, Smidt MP and van Hooft JA (2013) The serotonin 5-HT<sub>3</sub> receptor: a novel  
neurodevelopmental target. *Front Cell Neurosci* **7**, **Article 76**:1-8.
- García DA, Bujons J, Vale C and Suñol C (2006) Allosteric positive interactions of thymol  
with GABA<sub>A</sub> receptors in primary cultures of mouse cortical neurons. *Neuropharmacol*  
**50**:25-35.
- Ghosh B, Satyshur KA and Czajkowski C (2013) Propofol binding to the resting state of the  
*Gloeobacter violaceus* ligand-gated ion channel (GLIC) induces structural changes in  
the inter- and intrasubunit transmembrane domain (TMD) cavities. *J Biol Chem*  
**288**:17420-17431.
- Gill JK, Chatzidaki A, Ursu D, Sher E and Millar NS (2013) Contrasting properties of α7-  
selective orthosteric and allosteric agonists examined on native nicotinic acetylcholine  
receptors. *PLoS ONE* **8**:e55047.
- Gill JK, Dhankher P, Sheppard TD, Sher E and Millar NS (2012) A series of α7 nicotinic  
acetylcholine receptor allosteric modulators with close chemical similarity but diverse  
pharmacological properties. *Mol Pharmacol* **81**:710-718.
- Gill JK, Savolainen M, Young GT, Zwart R, Sher E and Millar NS (2011) Agonist activation of  
α7 nicotinic acetylcholine receptors via an allosteric transmembrane site. *Proc Natl*  
*Acad Sci USA* **108**:5867-5872.
- Hales TG and Lambert JJ (1991) The actions of propofol on inhibitory amino acid receptors  
of bovine adrenomedullary chromaffin cells and rodent central neurones. *Br J*  
*Pharmacol* **104**:619-628.



- Hargreaves AC, Gunthorpe MJ, Taylor CW and Lummis SCR (1996) Direct inhibition of 5-hydroxytryptamine<sub>3</sub> receptors by antagonists of the L-type Ca<sup>2+</sup> channels. *Mol Pharmacol* **50**:1284-1294.
- Harkness PC and Millar NS (2001) Inefficient cell-surface expression of hybrid complexes formed by the co-assembly of neuronal nicotinic acetylcholine receptor and serotonin receptor subunits. *Neuropharmacol* **41**:79-87.
- Hassaine G, Deluz C, Grasso L, Wyss R, B. TM, Hovius R, Graff A, Stahlberg H, Tomizaki T, Desmyter T, Moreau C, Li X-D, Poitevin F, Vogel H and Nury H (2014) X-ray structure of the mouse serotonin 5-HT<sub>3</sub> receptor. *Nature* **512**:276-281.
- Hetényi C and van der Spoel D (2006) Blind docking of drug-sized compounds to proteins with up to a thousand residues. *FEBS Lett* **580**:1447-1450.
- Hibbs RE and Gouaux E (2011) Principles of activation and permeation in an anion-selective Cys-loop receptor. *Nature* **474**:54-60.
- Hogg RC, Buisson B and Bertrand D (2005) Allosteric modulation of ligand-gated ion channels. *Biochem Pharmacol* **70**:1267-1276.
- Huey R, Morris GM, Olson AJ and Goodsell DS (2007) A semiempirical free energy force field with charge-based desolvation. *J Comput Chem* **28**:1145-1152.
- Jayakar SS, Dailey WP, Eckenhoff RG and Cohen JB (2013) Identification of propofol binding sites in a nicotinic acetylcholine receptor with a photoreactive nicotinic acetylcholine receptor with a photoreactive propofol analog. *J Biol Chem* **288**:6178-6189.
- Langmead CL and Christopoulos A (2006) Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. *Trends Pharmacol Sci* **27**:475-481.
- Lester HA, Dibas MI, Dahan DS, Leite JF and Dougherty DA (2004) Cys-loop receptors: new twists and turns. *Trends Neurosci* **27**:329-336.
- Lummis SCR (2012) 5-HT<sub>3</sub> receptors. *J Biol Chem* **287**:40239-40245.
- Lynagh T and Laube B (2014) Opposing effects of the anesthetic propofol at pentameric ligand-gated ion channels mediated by a common site. *J Neurosci* **34**:2155-2159.

- Machu TK and Harris RA (1994) Alcohols and anesthetics enhance the function of 5-hydroxytryptamine<sub>3</sub> receptors expressed in *Xenopus laevis* oocytes. *J Pharm Exp Ther* **271**:898-905.
- Maricq AV, Peterson AS, Brake AJ, Myers RM and Julius D (1991) Primary structure and functional expression of the 5HT<sub>3</sub> receptor, a serotonin-gated ion channel. *Science* **254**:432-437.
- Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK and Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. *J Comput Chem* **19**:1639-1662.
- Newman AS, Batis N, Grafton G, Caputo F, Brady CA, Lambert JJ, Peters JA, Gordon J, Brain KL, Powel AD and Barnes NM (2013) 5-Chloroindole: a potent allosteric modulator of the 5-HT<sub>3</sub> receptor. *Br J Pharmacol* **169**:1228-1238.
- Nury H, Van Renterghem C, Weng Y, Tran A, Baaden M, Dufresne V, Changeux J-P, Sonner JM, Delarue M and Corringer P-J (2011) X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel. *Nature* **469**:428-431.
- Nys M, Kester D and Ulens C (2013) Structural insights into Cys-loop receptor function and ligand recognition. *Biochem Pharmacol* **86**:1042-1053.
- Peixoto-Neves D, Silva-Alves KS, Gomes MDM, Lima FC, Lahlou S, Magalhães PJC, Ceccatto VM, Coelho-de-Souza AN and Leal-Cardoso JH (2009) Vasorelaxant effects of the monoterpenic phenol isomers, carvacrol and thymol, on rat isolated aorta. *Fund Clin Pharmacol* **24**:341-350.
- Priestley CM, Williamson EM, Wafford KA and Sattelle DB (2003) Thymol, a constituent of thyme essential oil, is a positive allosteric modulator of human GABA<sub>A</sub> receptors and a homo-oligomeric GABA receptor from *Drosophila melanogaster*. *Br J Pharmacol* **140**:1363-1372.
- Reiner GN, Delgado-Marín L, Olguín N, Sánchez-Redondo S, Sánchez-Borzone M, Rodríguez-Farré E, Suñol C and García DA (2013) Gabaergic pharmacological

- activity of propofol related compounds as possible enhancers of general anesthetics and interaction with membranes. *Cell Biochem Biophys* **67**:515-525.
- Thompson AJ (2013) Recent developments in 5-HT<sub>3</sub> receptor pharmacology. *Trends Pharmacol Sci* **34**:100-109.
- Thompson AJ, Lester HA and Lummis SCR (2010) The structural basis of function in Cys-loop receptors. *Quart Rev Biophys* **43**:449-499.
- Tong F, Gross AD, Dolan MC and Coats JR (2012) The phenolic monoterpene carvacrol inhibits the binding of nicotine to the housefly nicotinic acetylcholine receptor. *Pest Manag Sci* **69**:775-780.
- Trattng SM, Harpsøe K, Thygesen SB, Rahr LM, Ahring PK, Balle T and Jensen AA (2012) Discovery of a novel allosteric modulator of 5-HT<sub>3</sub> receptors: inhibition and potentiation of Cys-loop receptor signaling through a conserved transmembrane intersubunit site. *J Biol Chem* **287**:25241-25254.
- van Hooft JA, van der Haar E and Vijverberg HPM (1997) Allosteric potentiation of the 5-HT<sub>3</sub> receptor-mediated ion current in N1E-115 neuroblastoma cells by 5-hydroxyindole and analogues. *Neuropharmacol* **36**:649-653.
- Yang K-H, Galadari S, Isaev D, Petroianu G, Shippenberg TS and Oz M (2010) The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine<sub>3A</sub> receptor-mediated currents in *Xenopus laevis* oocytes. *J Pharm Exp Ther* **333**:547-554.
- Yevenes GE and Zeilhofer HU (2011) Allosteric modulation of glycine receptors. *Brit J Pharmacol* **164**:224-236.
- Yip GMS, Chen Z-W, Edge CJ, Smith CH, Dickinson R, Hohenester E, Townsend RR, Fuchs K, Sieghart W, Evers AS and Franks NP (2013) A propofol binding site on mammalian GABA<sub>A</sub> receptors identified by photolabeling. *Nature Chem Biol* **9**:715-720.
- Young GT, Broad LM, Zwart R, Astles PC, Bodkin M, Sher E and Millar NS (2007) Species selectivity of a nicotinic acetylcholine receptor agonist is conferred by two adjacent

extracellular  $\beta 4$  amino acids that are implicated in the coupling of binding to channel gating. *Mol Pharmacol* **71**:389-397.

Young GT, Zwart R, Walker AS, Sher E and Millar NS (2008) Potentiation of  $\alpha 7$  nicotinic acetylcholine receptors via an allosteric transmembrane site. *Proc Natl Acad Sci USA* **105**:14686-14691.

Zhou Q and Lovinger DM (1996) Pharmacologic characteristics of potentiation of 5-HT<sub>3</sub> receptors by alcohols and diethyl ether in NCB-20 neuroblastoma cells. *J Pharm Exp Ther* **278**:732-740.

## Footnotes

This work was supported by the Medical Research Council (MRC) via the Confidence in Concept Scheme [Grant MC\_PC\_12024]. Anne Doward was supported by an MRC Collaborative Award in Science and Engineering (CASE) PhD studentship that was co-funded by the MRC and Eli Lilly.

## Figure Legends

**Figure 1.** Chemical structures of the monoterpene compounds examined in this study.

**Figure 2.** Agonist responses with human and mouse 5-HT<sub>3A</sub>Rs expressed in *Xenopus* oocytes. Representative responses are shown with homomeric 5-HT<sub>3</sub>Rs containing the human 5-HT<sub>3A</sub> subunit (A), mouse 5-HT<sub>3A</sub> subunit (B), mouse/human 5-HT<sub>3A</sub> subunit chimera (C) and human/mouse 5-HT<sub>3A</sub> subunit chimera (D). In each case, responses are shown with 5-HT (100  $\mu$ M; *left*), carvacrol (100  $\mu$ M; *left middle*), thymol (100  $\mu$ M; *right middle*) and *p*-thymol (100  $\mu$ M; *right*). Vertical scale bar: 1  $\mu$ A (A and B), 0.5  $\mu$ A (C and D).

**Figure 3.** Desensitisation of human 5-HT<sub>3A</sub>Rs. Representative traces are shown, illustrating complete desensitisation of human 5-HT<sub>3A</sub>Rs expressed in *Xenopus* oocytes in response to long applications (> 7 minutes) of maximal concentrations of 5-HT (100  $\mu$ M; black trace) and thymol (300  $\mu$ M; red trace). Despite differences in the rates of activation, complete desensitisation was observed over a broadly similar timescale (approximately 8 minutes) with 5-HT and thymol.

**Figure 4.** Potentiation by carvacrol and thymol of submaximal concentrations of 5-HT. Representative traces illustrating potentiation by carvacrol (A) and thymol (B). In each case, responses are shown to an approximate  $EC_{25}$  concentration of 5-HT (0.6  $\mu$ M; *left*), either carvacrol or thymol (10  $\mu$ M; *middle*) and 5-HT (0.6  $\mu$ M) co-applied with carvacrol or thymol (10  $\mu$ M; *right*). Dose-response curves for 5-HT in the absence (closed circles) or presence of 10  $\mu$ M carvacrol (C; open circles) or 10  $\mu$ M thymol (D; open diamonds) with human 5-HT<sub>3A</sub>Rs expressed in *Xenopus* oocytes (means of four independent experiments). Note: the curve illustrating potentiation with carvacrol (C) has its origin at ~16%. This reflects that fact that carvacrol (at 10  $\mu$ M) has weak agonist effects (see Fig. 5A).

**Figure 5.** Agonist dose-response curves. Dose response curves for 5-HT (filled circles), carvacrol (open circles) and thymol (open diamonds) are illustrated for homomeric 5-HT<sub>3</sub>Rs containing the human 5-HT<sub>3A</sub> subunit (A), mouse 5-HT<sub>3A</sub> subunit (B), mouse/human 5-HT<sub>3A</sub> subunit chimera (C) and human/mouse 5-HT<sub>3A</sub> subunit chimera (D). Data are means of 4-5 independent experiments.

**Figure 6.** Amino acid sequence alignment of human and mouse 5-HT<sub>3A</sub> subunit transmembrane regions. Alignments are presented of the four transmembrane domain regions: TM1 (A), TM2 (B), TM3 (C) and TM4 (D). Amino acid differences in the transmembrane regions of the human and mouse 5-HT<sub>3A</sub> subunits are indicated by asterisks.

**Figure 7.** Characterisation of human 5-HT<sub>3A</sub>Rs containing a single point mutation (M259V) in TM1. A) Representative responses are shown with 5-HT (100  $\mu$ M; *left*), carvacrol (100  $\mu$ M; *middle*) and thymol (100  $\mu$ M; *right*). B) Dose-response curves are shown for 5-HT (filled circles), carvacrol (open circles) and thymol (open diamonds). Data are means of 4-8 independent experiments.

**Figure 8.** Characterisation of mouse 5-HT<sub>3A</sub>Rs containing four point mutations (A251V, V264M, C270Y and D274N) in TM1. A) Representative responses are shown with 5-HT (100  $\mu$ M; *left*), carvacrol (300  $\mu$ M; *middle*) and thymol (300  $\mu$ M; *right*). B) Dose-response curves are shown for 5-HT (filled circles), carvacrol (open circles) and thymol (open diamonds). Data are means of 4-10 independent experiments.

**Figure 9.** Competition radioligand binding. 5-HT caused complete displacement, in a concentration-dependent manner, of the orthosteric ligand [<sup>3</sup>H]-GR65630 from its extracellular binding site. In contrast no significant displacement of [<sup>3</sup>H]-GR65630 was observed with either carvacrol or thymol. All points are means  $\pm$  SEM from three independent experiments.

**Figure 10.** Computer docking simulations of carvacrol and thymol into a homology model of the human 5-HT<sub>3A</sub>R. Docking studies were performed with a homology model containing the transmembrane domain of two adjacent subunits from the human homomeric 5-HT<sub>3A</sub>R. The top panel is an image showing all five subunits of the pentameric receptor, viewed from the extracellular side, in which the backbone alpha-helices of the two subunits that were used for computer docking studies are shaded in light blue and green. A close-up view of the predicted ligand-binding site is also shown viewed from above (middle panel) and from the side (bottom panel). The lowest energy docked conformation of two ligands (-6.1 kcal/mol for carvacrol and -5.8 kcal/mol for thymol) was in very close proximity (within 6Å) to the side chain of M259 in TM1 of the human 5-HT<sub>3A</sub> subunit. The position of the lowest energy docked conformation of the two ligands was almost identical and was located in the intersubunit cavity between TM1 and TM2 helices of one subunit and the TM3 and TM4 helices of the adjacent subunit. The side chain of M259 is shown in yellow.

### Supplemental Data

PDB file of a homology model of the human 5-HT<sub>3A</sub> receptor transmembrane region. The homology model was derived from the previously reported mouse 5-HT<sub>3A</sub> receptor structure (PDB file 4PIR), but contains only the transmembrane regions (M1-M3 and M4) of two adjacent subunits from the homopentameric receptor.




**Table 1**

Agonist effects of 5-HT, carvacrol and thymol on wild-type, chimeric and mutated 5-HT<sub>3</sub>Rs.


Subunit (s)	5-HT	Carvacrol	Thymol
	$pEC_{50}$ ( $EC_{50}$ $\mu$ M)	$pEC_{50}$ ( $EC_{50}$ $\mu$ M) % of 5-HT response	$pEC_{50}$ ( $EC_{50}$ $\mu$ M) % of 5-HT response
h5-HT3A	6.19 $\pm$ 0.04 (0.7)	4.80 $\pm$ 0.07 (20.4) 64.1 $\pm$ 6.5 (n=6)	4.28 $\pm$ 0.04 (52.9) 79.5 $\pm$ 4.0 (n=11)
m5-HT3A	5.85 $\pm$ 0.04 (1.4)	N/A 0 (n=15)	N/A 0 (n=12)
h5-HT3A + h5-HT3B	5.36 $\pm$ 0.06 (4.4)	4.36 $\pm$ 0.19 (43.0) 22.9 $\pm$ 1.9 (n=3)	4.19 $\pm$ 0.20 (65.2) 23.2 $\pm$ 2.5 (n=3)
m/h5-HT3A	6.57 $\pm$ 0.03 (0.2)	4.03 $\pm$ 0.07 (98.0) 71.0 $\pm$ 2.8 (n=6)	4.12 $\pm$ 0.05 (75.5) 76.2 $\pm$ 2.5 (n=5)
h/m5-HT3A	5.78 $\pm$ 0.01 (1.7)	ND 0.1 $\pm$ 0.1 (n=8)	ND 0.2 $\pm$ 0.2 (n=9)
h5-HT3A (V246A)	ND	ND 37.8 $\pm$ 7.4 (n=4)	ND 70.0 $\pm$ 8.3 (n=5)
h5-HT3A (M259V)	6.13 $\pm$ 0.02 (0.7)	ND 0.6 $\pm$ 0.3 (n=8)***	ND 1.3 $\pm$ 0.7 (n=8)***
h5-HT3A (Y265C)	ND	ND 57.4 $\pm$ 11 (n=5)	ND 62.8 $\pm$ 6.4 (n=6)
h5-HT3A (N269D)	ND	ND 78.8 $\pm$ 8.8 (n=3)	ND 70.1 $\pm$ 5.8 (n=3)
h5-HT3A (M470T)	ND	ND 21.2 $\pm$ 4.2 (n=3)***	ND 48.3 $\pm$ 4.8 (n=3)***
m5-HT3A (V264M)	6.20 $\pm$ 0.03 (0.7)	N/A 0 (n=7)	N/A 0 (n=7)
m5-HT3A (A251V, V264M)	6.20 $\pm$ 0.04 (0.7)	ND 4.0 $\pm$ 0.1 (n=8)***	ND 4.2 $\pm$ 1.9 (n=8)***
m5-HT3A (V264M, C270Y)	5.85 $\pm$ 0.02 (1.5)	ND 2.3 $\pm$ 0.5 (n=10)	ND 1.5 $\pm$ 0.4 (n=10)
m5-HT3A (V264M, D274N)	6.17 $\pm$ 0.02 (0.8)	3.96 $\pm$ 0.11 (115) 9.3 $\pm$ 1.8 (n=7)***	3.97 $\pm$ 0.40 (107) 7.7 $\pm$ 1.2 (n=7)***
m5-HT3A (V264M, T481M)	5.94 $\pm$ 0.03 (1.2)	ND 0.5 $\pm$ 0.3 (n=9)	ND 1.4 $\pm$ 1.0 (n=10)
m5-HT3A (V264M, C270Y, D274N)	6.05 $\pm$ 0.02 (0.9)	3.79 $\pm$ 0.03 (159) 12.2 $\pm$ 1.6 (n=5)***	3.94 $\pm$ 0.04 (114) 21.2 $\pm$ 7.0 (n=5)***
m5-HT3A (A251V, V264M, C270Y, D274N)	6.15 $\pm$ 0.04 (0.7)	3.91 $\pm$ 0.03 (123) 31.8 $\pm$ 3.1 (n=10)***	3.93 $\pm$ 0.04 (118) 31.6 $\pm$ 1.3 (n=6)***

N/A = not applicable; ND = not determined. Data are means  $\pm$  SEM (n = 3-11). Significant differences between maximal responses (% of 5-HT) of mutated receptors and the corresponding wild-type receptor (mouse or human), determined by unpaired Student's t-test, are indicated (\*\*\*  $P$  < 0.001).


# Figure 1




Carvacrol




Thymol




*p*-Thymol




Propofol




Chlorothymol




*p*-Cymene




$\alpha$ -Terpineol



Citral




Linalool




Menthol

**Figure 2**




# Figure 3




# Figure 4

Molecular Pharmacology Fast Forward. Published on October 22, 2014 as DOI:  
This article has not been copyedited and formatted. The final version may differ.



# Figure 5



# Figure 6

## TM1

		*		*		*		*	
242	PLFYVVSLLLPSIFLMVMDIVGFYLP	269	Human 5-HT3A						
247	PLFYAVSLLLPSIFLMVVDIVGFCLPP	274	Mouse 5-HT3A						
		*		*		*		*	

## TM2

274	VSFKITLLLGYSVFLIIVS	292	Human 5-HT3A
279	VSFKITLLLGYSVFLIIVS	297	Mouse 5-HT3A



## TM3

303	PLIGVYFVVCMA LLVISLAE	322	Human 5-HT3A
308	PLIGVYFVVCMA LLVISLAE	327	Mouse 5-HT3A

## TM4



		*	
456	IYLLAVLAYSITLVMLWSIW	475	Human 5-HT3A
467	IYLLAVLAYSITLVTLWSIW	486	Mouse 5-HT3A

**Figure 7**






**Figure 8**



# Figure 9



# Figure 10

